MDGL - Madrigal Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
288.12
+3.24 (+1.14%)
市場開市。 截至 09:57AM EDT。
你目前的瀏覽器並不支援股價圖表
前收市價284.88
開市285.77
買盤286.52 x 1100
賣出價288.25 x 1300
今日波幅285.77 - 288.75
52 週波幅57.21 - 322.67
成交量10,920
平均成交量388,212
市值5.269B
Beta 值 (5 年，每月)-0.61
市盈率 (最近 12 個月)無
每股盈利 (最近 12 個月)-18.32
業績公佈日2023年8月02日 - 2023年8月07日
遠期股息及收益率無 (無)
除息日無
1 年預測目標價331.17
  • Benzinga

    Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says

    Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. JMP has raised the price target from $182 to $312 and reiterates its Market Outperform rating. Resmetirom looks approvable based on Phase 3 MAESTRO-NASH data, the analyst said. The analyst raised POS for resmetirom to 90% in both the U.S. and EU (from 70% and 60%, respectively) with peak sales of ~$5 billion and ~$1.5 billion (compared to $3 billion

  • Benzinga

    Madrigal Shares Skyrocket After Successful NASH Study

    Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. In the 52-week serial liver biopsy study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo. NASH resolution was observed in 26% and 30% in 80 mg and 100 mg doses, respectively, vs. 10% in the placebo. Related: Analysts

  • Benzinga

    Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

    Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. Consistent with the previous top-line data, the most frequently reported adverse event